Bacteriophage therapy in implant-related infections: an experimental study
- PMID: 23324958
- DOI: 10.2106/JBJS.K.01135
Bacteriophage therapy in implant-related infections: an experimental study
Abstract
Background: Implant-related infections with bacteria resistant to multiple antibiotics represent one of the major problems in orthopaedic surgery. It was our hypothesis that local application of bacteriophages, which are bacteria-destroying viruses, would be effective against biofilm-forming bacteria.
Methods: An implant-related infection model was created using methicillin-resistant Staphylococcus aureus (MRSA) in forty-eight rats and Pseudomonas aeruginosa in another forty-eight rats. Each group was divided into four subgroups; one subgroup received a bacterium-specific bacteriophage (Sb-1 in the MRSA group and PAT14 in the Pseudomonas aeruginosa group), one received antibiotic for fourteen days (20 mg/kg/day teicoplanin in the MRSA group, and 120 mg/kg/day imipenem + cilastatin and 25 mg/kg/day amikacin in the Pseudomonas group), one received antibiotic and bacteriophage, and one received no treatment. Animals receiving bacteriophage therapy were injected locally with 107 bacteriophages in a 0.1-mL suspension on three consecutive days. All animals were killed on the fifteenth day after initiation of treatment, and the tibia was excised. Results were assessed with use of microbiology, light microscopy, and electron microscopy.
Results: In the MRSA group, the antibiotic administration significantly decreased the number of colony-forming units per subject in quantitative cultures (control subgroup, 50,586; bacteriophage, 30,788; antibiotic, 17,165; antibiotic + bacteriophage, 5000; p = 0.004 for the comparison of the latter group with the control). Biofilm was absent only in the antibiotic + bacteriophage subgroup. In the Pseudomonas group, the number of colony-forming units per subject in quantitative cultures was significantly lower in each treatment subgroup compared with the control subgroup (control subgroup, 14,749; bacteriophage, 6484 [p = 0.016]; antibiotic, 2619 [p = 0.01]; antibiotic + bacteriophage, 1705 [p < 0.001]). The value in the antibiotic + bacteriophage subgroup was also significantly lower than the values in the other subgroups (p = 0.006). Biofilm thickness did not differ significantly among the subgroups in the Pseudomonas group.
Conclusions: The addition of bacteriophage treatment to an appropriate antibiotic regimen helped to dissolve the biofilm of both types of bacteria studied. This effect on MRSA was more pronounced than that on Pseudomonas aeruginosa.
Comment in
-
Exploring new strategies for infection treatment: commentary on an article by Cengiz Yilmaz, MD, et al.: "Bacteriophage therapy in implant-related infections. an experimental study".J Bone Joint Surg Am. 2013 Jan 16;95(2):e11 1-2. doi: 10.2106/JBJS.L.01419. J Bone Joint Surg Am. 2013. PMID: 23324967 No abstract available.
Similar articles
-
Antibiotics Enhance Prevention and Eradication Efficacy of Cathodic-Voltage-Controlled Electrical Stimulation against Titanium-Associated Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Biofilms.mSphere. 2019 May 1;4(3):e00178-19. doi: 10.1128/mSphere.00178-19. mSphere. 2019. PMID: 31043516 Free PMC article.
-
Regional antibiotic delivery for the treatment of experimental prosthetic graft infections.J Surg Res. 2009 Dec;157(2):223-6. doi: 10.1016/j.jss.2008.06.050. Epub 2008 Aug 14. J Surg Res. 2009. PMID: 19560786
-
Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm.Clin Orthop Relat Res. 2015 Jul;473(7):2270-82. doi: 10.1007/s11999-014-4130-8. Clin Orthop Relat Res. 2015. PMID: 25604874 Free PMC article.
-
Therapies against virulence products of Staphylococcus aureus and Pseudomonas aeruginosa.Semin Respir Crit Care Med. 2011 Apr;32(2):228-35. doi: 10.1055/s-0031-1275535. Epub 2011 Apr 19. Semin Respir Crit Care Med. 2011. PMID: 21506059 Review.
-
Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.APMIS Suppl. 2003;(116):1-47. APMIS Suppl. 2003. PMID: 14692154 Review.
Cited by
-
Benefits of Combined Phage-Antibiotic Therapy for the Control of Antibiotic-Resistant Bacteria: A Literature Review.Antibiotics (Basel). 2022 Jun 22;11(7):839. doi: 10.3390/antibiotics11070839. Antibiotics (Basel). 2022. PMID: 35884092 Free PMC article. Review.
-
Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.Int J Mol Sci. 2025 Feb 19;26(4):1755. doi: 10.3390/ijms26041755. Int J Mol Sci. 2025. PMID: 40004222 Free PMC article. Review.
-
Evaluation of the Activity of a Combination of Three Bacteriophages Alone or in Association with Antibiotics on Staphylococcus aureus Embedded in Biofilm or Internalized in Osteoblasts.Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02231-19. doi: 10.1128/AAC.02231-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31871084 Free PMC article.
-
Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study.Microbiol Spectr. 2021 Dec 22;9(3):e0173621. doi: 10.1128/spectrum.01736-21. Epub 2021 Dec 15. Microbiol Spectr. 2021. PMID: 34908439 Free PMC article.
-
Bacteriophages and Lysins in Biofilm Control.Virol Sin. 2020 Apr;35(2):125-133. doi: 10.1007/s12250-019-00192-3. Epub 2020 Mar 3. Virol Sin. 2020. PMID: 32125643 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources